Trials / Recruiting
RecruitingNCT05880537
Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry
Safety, Efficacy, & Use of Decellularized Femoral Artery Allograft for Arteriovenous Access for Hemodialysis: A Multi-center Prospective Registry Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- LifeNet Health · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,
Detailed description
The clinical objective of this prospective, observational, post market registry study, CR-21-005, is to assess the safety and efficacy of a decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery, LifeNet Health, Virginia Beach, VA) in the creation of vascular access for hemodialysis in patients with ESRD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Nexeon Arterial Venous Allograft | Nexeon AVX allograft for hemodialysis access in end stage renal disease |
Timeline
- Start date
- 2023-06-06
- Primary completion
- 2027-12-15
- Completion
- 2027-12-15
- First posted
- 2023-05-30
- Last updated
- 2025-04-02
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05880537. Inclusion in this directory is not an endorsement.